Diabetes-Related Complications and Costs in Medicare Beneficiaries with Comorbid Rheumatoid Arthritis and Diabetes Treated with Abatacept Versus Other Targeted DMARDs.

Rheumatol Ther · 2022 · PMC9314491 · PMID 35604547

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The key finding of this study was that patients treated with abatacept showed a trend towards lower T2DM-related HCRU and costs compared with TNFi and other non-TNFi.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.